Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Faeth Therapeutics, Inc

SNSE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$32.34

▲ +13.27%

Market Cap $835.68M · Vol 51.77K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$835.68M

Small Cap

Div Yield

N/A

EPS Growth

-157.83%

YoY

RSI (14)

59.75

Momentum

Beta

-0.24

vs Market

52W High

$37.90

14.67% below

52W Low

$7.21

348.54% above

Volume

51.77K

Avg 48.40K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

94.71%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Faeth Therapeutics, Inc (SNSE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SNSE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+32.60%

-2.36%

+63.17%

+255.78%

YTD

+203.09%

+344.23%

+45.68%

-79.66%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-21,085,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-61.78% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	-157.83%
Outstanding Shares	25.84M

Technical Indicators

50-Day SMA	$24.52
200-Day SMA	$19.80
RSI (14)	59.75
Beta	-0.24
52-Week High	$37.90
52-Week Low	$7.21

Volume Today	51.77K
Avg Daily Volume (30D)	48.40K
Relative Volume	1.07x
Volatility (10D)	108.95
Volatility (30D)	112.99
Free Float	94.71%

Analyst Consensus

BUY

Current Price $32.34

Mean Target $54.50

52W Low$7.21 52W High$37.90

Current

Target

$7.21 $37.90

Current Analyst target

+68.52% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00V3M3TR3

ISINN/A

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.